Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$19.61M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
973.63%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
-$143.1M
Q3 2024
Cash
Q3 2024
P/E
-0.09429
Nov 29, 2024 EST
Free Cash Flow
-$12.64M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017
Selling, General & Admin $22.84M $20.21M $20.95M $15.71M $8.360M $5.590M $3.500M
YoY Change 12.97% -3.52% 33.36% 87.92% 49.55% 59.71%
% of Gross Profit
Research & Development $24.12M $31.01M $52.42M $54.85M $42.33M $18.66M $20.59M
YoY Change -22.24% -40.84% -4.43% 29.56% 126.83% -9.36%
% of Gross Profit
Depreciation & Amortization $259.0K $100.0K $800.0K $400.0K $267.0K $127.0K $80.00K
YoY Change 159.0% -87.5% 100.0% 49.81% 110.24% 58.75%
% of Gross Profit
Operating Expenses $46.95M $31.01M $52.42M $54.85M $42.33M $18.66M $24.09M
YoY Change 51.4% -40.84% -4.43% 29.56% 126.83% -22.53%
Operating Profit -$49.26M -$51.23M -$73.37M -$70.55M -$50.69M -$24.26M
YoY Change -3.84% -30.18% 3.99% 39.18% 108.99%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017
Interest Expense -$9.822M $11.57M $7.194M $4.880M $3.031M $220.0K $190.0K
YoY Change -184.88% 60.84% 47.42% 61.0% 1277.73% 15.79%
% of Operating Profit
Other Income/Expense, Net
YoY Change

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017
Pretax Income -$59.08M -$62.29M -$80.53M -$74.23M -$51.94M -$23.90M -$23.91M
YoY Change -5.15% -22.65% 8.49% 42.93% 117.33% -0.05%
Income Tax $0.00 $70.00K $0.00 -$16.00K -$9.000K -$223.0K -$360.0K
% Of Pretax Income
Net Earnings -$59.08M -$62.22M -$80.53M -$74.22M -$51.93M -$23.68M -$23.55M
YoY Change -5.05% -22.74% 8.51% 42.92% 119.34% 0.54%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$1.33 -$2.30 -$3.123M -$2.984M -$2.093M -$972.1K -$966.7K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017
Cash & Short-Term Investments $18.26M $31.60M $71.22M $72.80M $112.3M $81.50M $14.20M
YoY Change -42.22% -55.63% -2.17% -35.17% 37.79% 473.94%
Cash & Equivalents $18.26M $4.266M $19.86M $15.90M $18.40M $14.80M $6.200M
Short-Term Investments $0.00 $27.33M $51.36M $56.90M $93.90M $66.70M $8.000M
Other Short-Term Assets $3.372M $6.938M $6.175M $5.200M $5.300M $1.500M $500.0K
YoY Change -51.4% 12.36% 18.75% -1.89% 253.33% 200.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $21.63M $38.54M $77.39M $77.90M $117.6M $83.90M $15.20M
YoY Change -43.87% -50.21% -0.65% -33.76% 40.17% 451.97%
Property, Plant & Equipment $1.283M $481.0K $823.0K $1.600M $1.700M $600.0K $300.0K
YoY Change 166.74% -41.56% -48.56% -5.88% 183.33% 100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $90.00K $1.881M $1.957M $1.500M $900.0K $500.0K $200.0K
YoY Change -95.22% -3.88% 30.47% 66.67% 80.0% 150.0%
Total Long-Term Assets $4.512M $5.501M $5.919M $6.200M $5.800M $4.200M $3.700M
YoY Change -17.98% -7.06% -4.53% 6.9% 38.1% 13.51%
Total Assets $26.14M $44.04M $83.31M $84.10M $123.4M $88.10M $18.90M
YoY Change
Accounts Payable $1.375M $3.581M $5.044M $5.100M $3.900M $3.900M $2.300M
YoY Change -61.6% -29.0% -1.1% 30.77% 0.0% 69.57%
Accrued Expenses $3.582M $9.798M $7.891M $8.800M $5.700M $2.600M $2.000M
YoY Change -63.44% 24.17% -10.33% 54.39% 119.23% 30.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.957M $13.38M $12.94M $14.00M $9.700M $6.400M $4.300M
YoY Change -62.95% 3.43% -7.61% 44.33% 51.56% 48.84%
Long-Term Debt $151.0M $139.6M $128.1M $63.40M $43.30M $20.20M $0.00
YoY Change 8.17% 9.04% 101.99% 46.42% 114.36%
Other Long-Term Liabilities $1.117M $0.00 $44.00K $400.0K $500.0K $0.00 $0.00
YoY Change -100.0% -89.0% -20.0%
Total Long-Term Liabilities $152.2M $139.6M $128.1M $63.80M $43.80M $20.20M $0.00
YoY Change 8.97% 9.0% 100.79% 45.66% 116.83%
Total Liabilities $157.3M $153.2M $141.3M $78.00M $53.80M $27.00M $4.800M
YoY Change 2.68% 8.42% 81.17% 44.98% 99.26% 462.5%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $1.8493 Million

About Galera Therapeutics, Inc.

Galera Therapeutics, Inc. is a clinical stage biotechnology company, which engages in developing and commercializing a pipeline of novel, proprietary therapeutics for cancer. The company is headquartered in Malvern, Pennsylvania and currently employs 7 full-time employees. The company went IPO on 2019-11-07. The Company’s lead product candidate, avasopasem manganese (avasopasem), is a highly selective small molecule dismutase mimetic that the Company is developing for the reduction of severe oral mucositis (SOM) in patients with head and neck cancer (HNC), the reduction of esophagitis in patients with lung cancer, and the reduction of cisplatin-induced kidney damage in patients with cancer. The Company’s second product candidate, rucosopasem manganese (rucosopasem), is in development to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. Rucosopasem is an orphan drug designation and orphan medicinal product designation for the treatment of pancreatic cancer.

Industry: Pharmaceutical Preparations Peers: Applied Therapeutics, Inc. DYADIC INTERNATIONAL INC Cidara Therapeutics, Inc. Quince Therapeutics, Inc. Scorpius Holdings, Inc. IN8BIO, INC. MUSTANG BIO, INC. Synaptogenix, Inc. Rubius Therapeutics, Inc.